

Styliani Papadaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5197921/publications.pdf>

Version: 2024-02-01

79
papers

7,326
citations

331670

21
h-index

74163

75
g-index

79
all docs

79
docs citations

79
times ranked

9768
citing authors

#	ARTICLE	IF	CITATIONS
1	Urine 8-Hydroxyguanine (8-OHG) in Patients Undergoing Surgery for Colorectal Cancer. <i>Journal of Investigative Surgery</i> , 2022, 35, 591-597.	1.3	4
2	Inflammation, Oxidative Stress, Vascular Aging and Atherosclerotic Ischemic Stroke. <i>Current Medicinal Chemistry</i> , 2022, 29, 5496-5509.	2.4	25
3	Oxidized phospholipids and lipoprotein(a): An update. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13710.	3.4	9
4	Anti-Cancer Properties of Stevia rebaudiana; More than a Sweetener. <i>Molecules</i> , 2022, 27, 1362.	3.8	22
5	Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants. <i>Platelets</i> , 2021, 32, 807-814.	2.3	8
6	Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events. <i>Journal of the American Heart Association</i> , 2021, 10, e018184.	3.7	11
7	The Effect of Platelet-Rich Plasma on Endothelial Progenitor Cell Functionality. <i>Angiology</i> , 2021, 72, 776-786.	1.8	4
8	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , 2021, 322, 77-81.	0.8	8
9	MO474 PCSK9 LEVELS AND MARKERS OF INFLAMMATION, OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION IN A POPULATION OF NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS: IS THERE AN ASSOCIATION?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
10	Interleukin-17A Triggers the Release of Platelet-Derived Factors Driving Vascular Endothelial Cells toward a Pro-Angiogenic State. <i>Cells</i> , 2021, 10, 1855.	4.1	7
11	Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-8.	4.0	12
12	Transcriptional Profiling of Tumorspheres Reveals TRPM4 as a Novel Stemness Regulator in Breast Cancer. <i>Biomedicines</i> , 2021, 9, 1368.	3.2	9
13	SARS-CoV-2 infection and thrombotic complications: a narrative review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 111-123.	2.1	30
14	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
15	Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity – the effect of vitamin D supplementation: a pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2020, 5, 64-71.	1.0	9
16	The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. <i>Atherosclerosis</i> , 2019, 288, 9-16.	0.8	103
17	FP372 PCSK9 AND INDICES OF CARDIOVASCULAR MORBIDITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	1
18	Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?. <i>Angiology</i> , 2019, 70, 896-907.	1.8	22

#	ARTICLE	IF	CITATIONS
19	<p>Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib</p>. Drug Design, Development and Therapy, 2019, Volume 13, 4225-4238.	4.3	3
20	Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives. Current Pharmaceutical Design, 2019, 24, 3622-3633.	1.9	12
21	Effect of combined vitamin D administration plus dietary intervention on oxidative stress markers in patients with metabolic syndrome: A pilot randomized study. Clinical Nutrition ESPEN, 2019, 29, 198-202.	1.2	12
22	Circulating progenitor cells and their interaction with platelets in patients with an acute coronary syndrome. Platelets, 2019, 30, 314-321.	2.3	5
23	Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; ĩ Randomised Clinical Trial. Current Vascular Pharmacology, 2019, 17, 635-643.	1.7	2
24	Comparative Anti-Platelet Profiling Reveals a Potent Anti-Aggregatory Effect of CD34+ Progenitor Cell-Derived Late-Outgrowth Endothelial Cells in vitro. Journal of Vascular Research, 2018, 55, 13-25.	1.4	6
25	Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role. Journal of Biomedical Research, 2018, 32, 13.	1.6	25
26	Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability. Methods in Molecular Biology, 2018, 1824, 371-385.	0.9	4
27	Autoantibodies to ox-LDL in Sjögren's syndrome: are they atheroprotective?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 61-67.	0.8	5
28	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	3.4	208
29	High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2017, 376, 112-116.	0.6	77
30	Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2609-2618.	2.4	13
31	Clopidogrel Therapy in Patients with Cardiovascular Disease Undergoing Transurethral Resection of the Prostate: A Step Towards Individualization. Drugs and Aging, 2017, 34, 917-923.	2.7	0
32	Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity. Journal of Lipid Research, 2017, 58, 1869-1883.	4.2	36
33	Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 133-141.	2.0	2
34	Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study. Archives of Medical Sciences Atherosclerotic Diseases, 2017, 2, 46-51.	1.0	17
35	Antiplatelet Agents and Anticoagulants: From Pharmacology to Clinical Practice. Current Pharmaceutical Design, 2017, 23, 1279-1293.	1.9	12
36	Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study. Current Vascular Pharmacology, 2016, 14, 474-480.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Deconvoluting the Dual Antiplatelet Activity of a Plant Extract. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 4511-4521.	5.2	13
38	Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34 + progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. <i>Atherosclerosis</i> , 2016, 251, 240-247.	0.8	10
39	Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy. <i>Platelets</i> , 2016, 27, 812-820.	2.3	3
40	Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 516-525.	2.0	6
41	Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Angiology</i> , 2016, 67, 208-211.	1.8	0
42	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , 2016, 15, 8-14.	1.9	7
43	Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 904-916.	2.8	91
44	The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 276-283.	2.0	8
45	Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPAR β -Activating Capacity. <i>Angiology</i> , 2015, 66, 36-42.	1.8	7
46	Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial. <i>Current Vascular Pharmacology</i> , 2015, 13, 809-818.	1.7	3
47	Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents. <i>Current Medical Research and Opinion</i> , 2014, 30, 51-54.	1.9	0
48	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 936-944.	1.3	20
49	Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A α (Lp-PLA α) Bound to LDL and HDL. <i>Current Pharmaceutical Design</i> , 2014, 20, 6256-6269.	1.9	55
50	Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives. <i>Current Pharmaceutical Design</i> , 2013, 19, 3827-3840.	1.9	16
51	Clopidogrel Generic Formulations in the Era of New Antiplatelets: A Systematic Review. <i>Current Vascular Pharmacology</i> , 2013, 12, 766-777.	1.7	13
52	Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2012, 53, 1670-1678.	4.2	53
53	Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 149-158.	1.8	11
54	Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2053-2060.	2.8	52

#	ARTICLE	IF	CITATIONS
55	The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. <i>Platelets</i> , 2012, 23, 121-131.	2.3	18
56	Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 319-336.	3.1	44
57	A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits. <i>Platelets</i> , 2011, 22, 361-370.	2.3	3
58	Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2). <i>Current Pharmaceutical Design</i> , 2011, 17, 3656-3661.	1.9	17
59	Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress. <i>Lipids</i> , 2011, 46, 341-348.	1.7	30
60	Mechanisms of platelet activation and modification of response to antiplatelet agents. <i>Hellenic Journal of Cardiology</i> , 2011, 52, 128-40.	1.0	1
61	Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β^2 -thalassemia. <i>Journal of Lipid Research</i> , 2010, 51, 3331-3341.	4.2	20
62	The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 327-338.	2.4	139
63	Inhibition of platelet activation by peptide analogs of the β^3 -intracellular domain of platelet integrin α IIb β^3 conjugated to the cell-penetrating peptide Tat(48-60). <i>Platelets</i> , 2009, 20, 539-547.	2.3	9
64	Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: The ATTICA Study. <i>Atherosclerosis</i> , 2009, 206, 303-308.	0.8	21
65	Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. <i>Atherosclerosis</i> , 2008, 196, 289-297.	0.8	22
66	Acute and long-term antiplatelet therapy. <i>Drugs of Today</i> , 2008, 44, 331.	1.1	4
67	Oxidative Stress Is Progressively Enhanced With Advancing Stages of CKD. <i>American Journal of Kidney Diseases</i> , 2006, 48, 752-760.	1.9	328
68	Comparative Antioxidant Effectiveness of White and Red Wine and Their Phenolic Extracts Towards Low-Density Lipoprotein Oxidation. <i>Food Biotechnology</i> , 2005, 19, 1-14.	1.5	8
69	Alterations of Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activities in Patients on Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2004, 24, 580-589.	2.3	20
70	Effect of synthetic peptides corresponding to residues 313-332 of the α IIb β^3 subunit on platelet activation and fibrinogen binding to α IIb β^3 . <i>FEBS Journal</i> , 2004, 271, 855-862.	0.2	26
71	Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. <i>Atherosclerosis</i> , 2004, 177, 193-201.	0.8	43
72	Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. <i>Atherosclerosis Supplements</i> , 2002, 3, 57-68.	1.2	274

#	ARTICLE	IF	CITATIONS
73	Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein. <i>Biochemical Journal</i> , 2001, 357, 457-464.	3.7	29
74	Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. <i>Cardiovascular Research</i> , 1999, 43, 183-191.	3.8	20
75	PAF-acetylhydrolase activity on Lp(a) before and during Cu ²⁺ -induced oxidative modification in vitro. <i>Atherosclerosis</i> , 1996, 125, 121-134.	0.8	46
76	PAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human Plasma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1764-1773.	2.4	193
77	Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation. <i>Lipids</i> , 1993, 28, 1119-1124.	1.7	12
78	A PAF-acetylhydrolase activity in <i>Tetrahymena pyriformis</i> cells. <i>FEBS Letters</i> , 1991, 288, 147-150.	2.8	15
79	1-O-Alkyl-2-acetyl-sn-glycerol-3-phosphorylcholine (PAF) is a minor lipid component in <i>Tetrahymena pyriformis</i> cells. <i>FEBS Letters</i> , 1986, 208, 52-55.	2.8	19